<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>cc1003</ui>
   <ji>CCJ</ji>
   <fm>
      <dochead>Meeting abstract</dochead>
      <bibl>
         <title>
            <p>Noncardioplegic myocardial protection in high-risk coronary artery bypass grafting</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Kleikamp</snm>
               <fnm>G</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Rei&#946;</snm>
               <fnm>N</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Mirow</snm>
               <fnm>N</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Hansky</snm>
               <fnm>B</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>El-Banayosy</snm>
               <fnm>A</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A6">
               <snm>Minami</snm>
               <fnm>K</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A7">
               <snm>K&#246;rfer</snm>
               <fnm>R</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Department of Thoracic and Cardiovascular Surgery, Heart Center NRW, Ruhr University of Bochum, Bad Oeynhausen, Germany</p>
            </ins>
         </insg>
         <source>Critical Care</source>
         <supplement>
            <title>
               <p>3rd International Symposium on the Pathophysiology of Cardiopulmonary Bypass. Myocardial cell damage and myocardial protection</p>
            </title>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>3rd International Symposium on the Pathophysiology of Cardiopulmonary Bypass. Myocardial cell damage and myocardial protection</p>
            </title>
            <location>Aachen, Germany</location>
            <date-range>16 December 2000</date-range>
         </conference>
         <issn>1364-8535</issn>
         <pubdate>2001</pubdate>
         <volume>5</volume>
         <issue>Suppl B</issue>
         <fpage>P10</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/cc1003</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>12</day>
               <month>2</month>
               <year>2001</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>6</day>
               <month>3</month>
               <year>2001</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2001</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <meta>
      <classifications>
         <classification type="BMC" subtype="old_arx_id">cc-5-2-105-p10</classification>
      </classifications>
   </meta>
   <bdy>
      <sec>
         <st>
            <p>Introduction</p>
         </st>
         <p>This study was undertaken to determine whether intermittent aortic cross-clamping in the fibrillating heart can be used successfully in high-risk coronary artery bypass grafting.</p>
      </sec>
      <sec>
         <st>
            <p>Method</p>
         </st>
         <p>From 1 January 1988 to 30 April 2000, 25,887 patients underwent isolated coronary bypass grafting for coronary artery disease at our institution. In all cases, myocardial protection consisted of intermittent aortic cross-clamping in the fibrillating heart under mild hypothermia. A total of 908 patients (797 male [88%]; mean age 60.1 &#177; 9.5 years, range 29-78 years) were suffering from ischaemic cardiomyopathy defined as global (left ventricular ejection fraction &lt;30%) and regional wall motion abnormalties. The pre-, peri- and postoperative data for this subgroup were entered prospectively into a database.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>Mean aortic cross-clamp time was 25.01 &#177; 8.2 min (range 0-46 min), mean perfusion time was 60.8 &#177; 26.3 min (range 19-336 min), and the number of bypass grafts per patient was 3.11 &#177; 0.927. Weaning from extracorporeal circulation was possible without catecholamines in 348 patients (38%); 560 (62%) received dopamine intravenously. Intra-aortic balloon counterpulsation was used in 85 patients (9%) and assist devices were used in nine patients. Twenty-eight patients (3.1%) suffered from perioperative myocardial infarction, 96 patients developed ventricular arrhythmia and 191 atrial fibrillation. Ventilatory support for longer than 24 h was required by 118 patients. Eighteen patients (2.0%) died within 30 days of the operation.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusion</p>
         </st>
         <p>Intermittent aortic cross-clamping in the fibrillating heart can be used safely for myocardial protection in all patients undergoing surgical revascularization. The results even in this high-risk group of patients compare favourably with all published series utilizing other forms of myocardial protection. Furthermore, this method is easy to use and cost neutral.</p>
      </sec>
   </bdy>
</art>
